Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Biotechnology

Biocon Limited, together with its subsidiaries, engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. It operates through four segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company offers generic formulations and API products, including anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology, and other products; novel biologics products, such as head and neck cancer molecule; novel pipeline products comprising psoriasis molecules; and biosimilars products consisting of insulins, trastuzumab, pegfilgrastim, and bevacizumab. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer good, and agrochemical companies. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.

Revenue projections:

Revenue projections for BIOCON
Revenue projections for BIOCON

Biocon Limited's revenue projections indicate a decrease from last year's performance, which could lead to investor caution. A fall in revenue is likely to negatively impact the company's profitability, causing concern for shareholders who may view this as a signal of declining financial health.

Financial Ratios:

currentRatio 1.221000
forwardPE 35.331757
debtToEquity 42.145000
earningsGrowth -0.725000
revenueGrowth 0.023000
grossMargins 0.663810
operatingMargins 0.112230
trailingEps 2.830000
forwardEps 11.774110

Biocon Limited's current ratio of 1.221 shows that the company has ample resources to service its short-term debt. This indicates a solid financial position, as Biocon Limited can rely on its cash reserves and current assets to cover its immediate liabilities without strain.
Biocon Limited's low earnings and revenue growth highlight a potential decline in profitability. This suggests that the company's financial health may be weakening, and profits could shrink as a result.
BIOCON's negative gross and operating margins suggest that the company is struggling to cover its production and operating costs, leading to losses. This reflects a weakened financial state and potential difficulties in sustaining profitability.
BIOCON's forward EPS exceeding its trailing EPS reflects expectations of increased profitability for the current year. This suggests that the company is projected to achieve higher earnings than in the previous financial year, signaling positive growth and improved financial health.

Price projections:

Price projections for BIOCON
Price projections for BIOCON

BIOCON's stock price has consistently been near the lower edge of expected values, indicating potential struggles in meeting growth projections. This trend may reflect a cautious market sentiment toward the company.

Recommendation changes over time:

Recommendations trend for BIOCON
Recommendations trend for BIOCON


The recent buy bias for Biocon Limited from analysts signals strong confidence in the stock's potential. This positive sentiment could encourage investors to see Biocon Limited as a smart place to invest their money, especially those looking for stable, long-term returns in a well-established company.